Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute


About the Immunology Program

AHCMCC2 - Image - Yoji Shimizu 180x172Program Leader: Yoji Shimizu, Ph.D.

The Immunology Program has 21 members from departments in the University of Minnesota Medical School, the College of Veterinary Medicine, and the College of Science and Engineering.

The scientific goal of the Immunology Program is to define the basic mechanisms that control adaptive immunity in order to develop immunotherapies that overcome the significant barriers associated with generating a durable immune response against tumor-associated antigens.

Research themes:

  • Mechanisms of lymphocyte tolerance
  • Lymphocyte activation and signal transduction
  • Mechanisms of lymphocyte development
  • Tumor immunology and immunotherapy
Program Meetings

The Immunology Program meetings are held concurrent with meetings of the Center for Immunology.

    Research Program Members
  • AHCMCC - Image - 70x80 - Paul Bohjanen

    Paul Bohjanen, M.D., Ph.D.
    Role of mRNA decay in regulating T cell activation and function

    AHCMCC - Image - 70x80 - Michael Farrar

    Michael Farrar, Ph.D.
    How cytokines and cytokine-dependent signal transduction pathways control regulatory T cell development and B cell leukemia

    AHCMCC2 - Image - 70x80 - Brian Fife

    Brian Fife, Ph.D.
    The PD-1 negative regulatory pathway in T cells and its role in controlling autoimmunity and preventing transplant rejection

    AHCMCC2 - Image - Tanya Freedman70x80

    Tanya Freedman, Ph.D.
    How inflammation modulates macrophage responsiveness, including in the inflammatory tumor microenvironment, especially in breast cancer; the regulation of proto-oncogenic signaling proteins like the Src family kinases

    AHCMCC2 - Image - 70x80 - Thomas Griffith

    Thomas Griffith, Ph.D.
    The immunotherapeutic potential of TRAIL in preclinical models of advanced renal cell carcinoma and breast cancer

    AHCMCC - Image - 70x80 - Kris Hogquist

    Kris Hogquist, Ph.D.
    Molecular mechanisms of T cell development in the thymus; analysis of transgenic and gene-deficient mice, gene expression profiling, and RNAi "knock-down" analysis;immune response to the Epstein Barr Virus - a chronic viral infection associated with cancer and autoimmunity in humans

    AHCMCC - Image - 70x80 - Stephen Jameson

    Stephen Jameson, Ph.D.
    Mechanisms that regulate the development and maintenance of T cells in the body; T cell homeostasis in response to lymphopenia which offers an opportunity to enhance the function of residual T cells in lymphodepleted individuals, including cancer patients receiving radio- or chemotherapy

    AHCMCC - Image - 70x80 - Marc Jenkins

     Marc Jenkins, Ph.D.
    Investigation of CD4+ helper T and B cell activation in vivo by directly tracking antigen-specific cells, with the goal of achieving a basic understanding of lymphocyte signal transduction, proliferation, and differentiation so that these processes can be manipulated to improve vaccines and prevent autoimmunity

    AHCMCC2 - Image - Langlois70x80

    Ryan A. Langlois, Ph.D.
    The interplay between innate and adaptive immune responses in the lung; mechanisms that drive immunopathology, cell death/survival and healing within the lung

    AHCMCC - Image - 70x80 - Walter Low

    Walter Low, Ph.D.
    Development of immunotherapeutic approaches for the treatment of brain tumors

    AHCMCC2 - Image - Masopust_70x80

    David Masopust, Ph.D.
    Resident memory T cells, cytotoxic T cell migration and function within tissues, and CD8 T cell vaccines

    AHCMCC - Image - 70x80 - Jeffrey Miller

    Jeffrey Miller, M.D.
    How undifferentiated stem cells develop into functioning NK cell lymphocytes and the manipulation of NK cells to treat or prevent cancer relapse; targeted immunotherapy to treat human cancer

    AHCMCC2 - Image - 70x60 - Christopher Moertel

    Christopher Moertel, M.D.
    Clinical interests include pediatriac neuro-oncology; rare pediatric tumors; neurofibromatosis-associated neoplasia; and the therapy of children with brain and spinal cord tumors.

    AHCMCC - Image - 70x80 - Daniel Mueller

    Daniel Mueller, M.D.
    Biological and biochemical nature of immune self-tolerance and application to the treatment of autoimmune disease, allograft rejection, and immunotherapy of cancer

    AHCMCC - Image - 70x80 - Christopher Pennell

    Christopher Pennell, Ph.D.
    Enhancing the efficacy of DNA-based vaccines for cancer therapy

    AHCMCC - Image - 70x80 - Erik Peterson

    Erik Peterson, M.D.
    The role of adaptor proteins in T cell development, regulation of T cell-dependent autoimmunity, and immune cell transduction

    AHCMCC - Image - 70x80 - Elizabeth Pluhar

    Liz Pluhar, D.V.M., Ph.D.
    Gene therapy for glioblastoma multiforme (GBM) and developing dogs with spontaneous glioma as an exceptional large animal model for human GBM and mengingiomas

    AHCMCC2 - Image - 70x80 - Daniel Saltzman

    Daniel Saltzman, M.D., Ph.D.
    Development of an attenuated strain of Salmonella typhimurium as an anti-cancer therapy capable of local delivery of immunostimulatory cytokines

    AHCMCC - Image - 70x80 - Yoji Shimizu

    Yoji Shimizu, Ph.D.
    Intracellular signal transduction events that regulate adhesion interactions critical for effective antigen-specific immune responses and cell trafficking

    AHCMCC2 - Image - 70x80 - Vaiva Vezys

    Vaiva Vezys, Ph.D.
    Investigation of how T cell tolerance to self-antigens, tumor antigens, and proteins from chronic infections is induced and maintained; development of methods for reversing established tolerance to these types of proteins and their translation to the clinic

    AHCMCC2 - Content - Bruce Walcheck_70x80

    Bruce Walcheck, Ph.D.
    Mechanisms that direct leukocytes to tissue locations and that regulate inflammation and cancer cell killing

    AHCMCC2 - Image - 70x80 - Chun Wang

    Chun Wang, Ph.D.
    Development of novel polymer-based biomaterials for the delivery of cancer chemo- and immunotherapeutics

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on March 29, 2016